The analysis identified that the prioritized tumor types, that is, colorectal cancer, SCCHN, and DLBCL, had tumors with higher levels of CD47-SIRPα and macrophage infiltration, and thus may be suitable targets for BMS-986351 treatment. This evidence concerns the gene SIRPA and neoplasm.